ES2613509T3 - Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol - Google Patents

Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol Download PDF

Info

Publication number
ES2613509T3
ES2613509T3 ES11760963.6T ES11760963T ES2613509T3 ES 2613509 T3 ES2613509 T3 ES 2613509T3 ES 11760963 T ES11760963 T ES 11760963T ES 2613509 T3 ES2613509 T3 ES 2613509T3
Authority
ES
Spain
Prior art keywords
methyl
ethyl
imidazol
benzyl ester
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11760963.6T
Other languages
English (en)
Spanish (es)
Inventor
Ken Chow
Mohammed I. Dibas
John E. Donello
Michael E. Garst
Daniel W. Gil
Liming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2613509(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2613509T3 publication Critical patent/ES2613509T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES11760963.6T 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol Active ES2613509T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US383370P 2010-09-16
PCT/US2011/052004 WO2012037499A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Publications (1)

Publication Number Publication Date
ES2613509T3 true ES2613509T3 (es) 2017-05-24

Family

ID=44675870

Family Applications (10)

Application Number Title Priority Date Filing Date
ES11760963.6T Active ES2613509T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
ES18160174T Active ES2781681T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para reducir la presión intraocular
ES16161922.6T Active ES2684055T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para reducir la presión intraocular
ES16161921T Active ES2737230T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas
ES16161923T Active ES2760920T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
ES16161920.0T Active ES2687420T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para tratar enfermedades y afecciones de la piel
ES19194325T Active ES2904479T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
ES11760958.6T Active ES2593612T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas
ES11760962.8T Active ES2607084T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para rebajar la presión intraocular
ES18157147T Active ES2788051T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas

Family Applications After (9)

Application Number Title Priority Date Filing Date
ES18160174T Active ES2781681T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para reducir la presión intraocular
ES16161922.6T Active ES2684055T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para reducir la presión intraocular
ES16161921T Active ES2737230T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas
ES16161923T Active ES2760920T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
ES16161920.0T Active ES2687420T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para tratar enfermedades y afecciones de la piel
ES19194325T Active ES2904479T3 (es) 2010-09-16 2011-09-16 Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
ES11760958.6T Active ES2593612T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas
ES11760962.8T Active ES2607084T3 (es) 2010-09-16 2011-09-16 Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para rebajar la presión intraocular
ES18157147T Active ES2788051T3 (es) 2010-09-16 2011-09-16 Pro-fármacos éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol para tratar enfermedades retinianas

Country Status (28)

Country Link
US (9) US8653123B2 (enExample)
EP (13) EP3078376B1 (enExample)
JP (4) JP2013537236A (enExample)
KR (7) KR101952457B1 (enExample)
CN (5) CN105412092B (enExample)
AR (4) AR083018A1 (enExample)
AU (4) AU2011301856C1 (enExample)
BR (4) BR112013006352A2 (enExample)
CA (8) CA2812195A1 (enExample)
CL (4) CL2013000735A1 (enExample)
CY (3) CY1121024T1 (enExample)
DK (9) DK2616069T3 (enExample)
ES (10) ES2613509T3 (enExample)
HU (5) HUE038698T2 (enExample)
IL (4) IL225282A0 (enExample)
MX (4) MX2013003009A (enExample)
MY (4) MY173846A (enExample)
NZ (1) NZ608751A (enExample)
PL (7) PL3050563T3 (enExample)
PT (7) PT3348264T (enExample)
RU (4) RU2612351C2 (enExample)
SG (4) SG188572A1 (enExample)
SI (5) SI3348264T1 (enExample)
TR (1) TR201909249T4 (enExample)
TW (4) TWI591058B (enExample)
UA (1) UA112973C2 (enExample)
WO (4) WO2012037499A1 (enExample)
ZA (4) ZA201302193B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518007A (ja) 2009-02-13 2012-08-09 アラーガン インコーポレイテッド （３‐（１‐（１ｈ‐イミダゾール‐４‐イル）エチル）‐２‐メチルフェニル）メタノールを含む医薬組成物
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
WO2013016073A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
AU2022258105A1 (en) * 2021-04-16 2023-10-26 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
KR20250141793A (ko) * 2023-02-08 2025-09-29 보슈 롬 아일랜드 리미티드 시력을 개선시키기 위한 알파-2-아드레날린성 효능제
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH09505298A (ja) 1993-11-15 1997-05-27 シェーリング コーポレイション Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
EA010392B1 (ru) * 2003-05-27 2008-08-29 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CN1823518A (zh) * 2003-07-14 2006-08-23 皇家飞利浦电子股份有限公司 投影设备
CA2538445A1 (en) 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
MXPA06013649A (es) 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN101031549A (zh) * 2004-09-24 2007-09-05 阿勒根公司 作为特异性α2肾上腺素能激动剂的4－（苯甲基和取代苯甲基）－咪唑－2－硫酮
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
AU2010210513A1 (en) 2009-02-06 2011-09-01 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors
JP2012518007A (ja) * 2009-02-13 2012-08-09 アラーガン インコーポレイテッド （３‐（１‐（１ｈ‐イミダゾール‐４‐イル）エチル）‐２‐メチルフェニル）メタノールを含む医薬組成物
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Also Published As

Publication number Publication date
US8853251B2 (en) 2014-10-07
SI3338777T1 (sl) 2020-08-31
SI3050564T1 (sl) 2020-02-28
AU2011301847B2 (en) 2016-02-11
PL2616068T3 (pl) 2016-11-30
HUE038698T2 (hu) 2018-11-28
WO2012037499A1 (en) 2012-03-22
KR101840501B1 (ko) 2018-05-04
PT3050564T (pt) 2019-12-11
US20130289088A1 (en) 2013-10-31
SG188570A1 (en) 2013-04-30
MX2013003002A (es) 2013-06-28
HK1185538A1 (zh) 2014-02-21
TW201305116A (zh) 2013-02-01
SI3050563T1 (sl) 2018-10-30
ES2684055T3 (es) 2018-10-01
KR20140005154A (ko) 2014-01-14
UA112973C2 (uk) 2016-11-25
AR083020A1 (es) 2013-01-23
US8492422B2 (en) 2013-07-23
CA2812197C (en) 2024-01-02
CL2013000736A1 (es) 2013-07-12
CN103200942A (zh) 2013-07-10
DK2616069T3 (en) 2016-12-19
US20150148394A1 (en) 2015-05-28
US8501796B2 (en) 2013-08-06
ES2737230T3 (es) 2020-01-10
US20120136036A1 (en) 2012-05-31
US20120142746A1 (en) 2012-06-07
DK3050563T3 (en) 2018-08-13
EP3636263A1 (en) 2020-04-15
CN103209694A (zh) 2013-07-17
RU2612351C2 (ru) 2017-03-07
EP3053576A1 (en) 2016-08-10
HUE048725T2 (hu) 2020-09-28
EP2616066B1 (en) 2016-07-13
EP3050563A1 (en) 2016-08-03
JP2013540749A (ja) 2013-11-07
IL225278A0 (en) 2013-06-27
AU2011301932B2 (en) 2016-02-25
DK2616068T3 (en) 2016-08-29
EP3338777B1 (en) 2020-02-05
ES2781681T3 (es) 2020-09-04
SI3348264T1 (sl) 2020-07-31
EP3348264A1 (en) 2018-07-18
EP3338777A1 (en) 2018-06-27
MX2013003004A (es) 2013-06-28
KR20140003407A (ko) 2014-01-09
CA2811559A1 (en) 2012-03-22
CN103221045A (zh) 2013-07-24
KR101952457B1 (ko) 2019-02-26
CL2013000735A1 (es) 2013-11-29
KR20190022895A (ko) 2019-03-06
PL3050563T3 (pl) 2018-12-31
AU2011301856C1 (en) 2016-09-08
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
EP3078376B1 (en) 2019-03-27
PT3053576T (pt) 2018-10-08
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
AR083019A1 (es) 2013-01-23
EP2616067A1 (en) 2013-07-24
PT3338777T (pt) 2020-05-06
HK1185541A1 (zh) 2014-02-21
DK3348264T3 (da) 2020-03-23
TR201909249T4 (tr) 2019-07-22
CL2013000734A1 (es) 2013-11-08
BR112013006352A2 (pt) 2016-06-28
PT3348264T (pt) 2020-04-02
RU2013116405A (ru) 2014-10-27
MX2013003009A (es) 2013-06-28
PL3348264T3 (pl) 2020-08-24
KR102104760B1 (ko) 2020-04-27
IL225278A (en) 2015-11-30
KR20130114140A (ko) 2013-10-16
WO2012037453A1 (en) 2012-03-22
DK3078376T3 (da) 2019-06-24
ZA201302288B (en) 2013-11-27
KR101840500B1 (ko) 2018-03-20
TWI591058B (zh) 2017-07-11
PT2616069T (pt) 2016-12-06
EP3050564B1 (en) 2019-09-04
EP3078376A1 (en) 2016-10-12
EP2616067B1 (en) 2016-05-18
PT3050563T (pt) 2018-10-01
CA2812191C (en) 2021-04-13
JP2013537236A (ja) 2013-09-30
ES2788051T3 (es) 2020-10-20
ZA201302291B (en) 2013-11-27
PL3050564T3 (pl) 2020-06-01
EP3050564A1 (en) 2016-08-03
CA3116249A1 (en) 2012-03-22
EP2616069A1 (en) 2013-07-24
ES2760920T3 (es) 2020-05-18
MX2013003008A (es) 2013-06-28
AU2011301847A1 (en) 2013-05-02
AU2011301856A1 (en) 2013-05-02
PL2616069T3 (pl) 2017-04-28
SI3053576T1 (sl) 2018-11-30
JP6045495B2 (ja) 2016-12-14
CA2812191A1 (en) 2012-03-22
EP3053576B1 (en) 2018-05-16
AU2011301901A1 (en) 2013-05-02
CN105412092B (zh) 2020-11-17
NZ608751A (en) 2015-04-24
TW201240661A (en) 2012-10-16
ES2607084T3 (es) 2017-03-29
ES2687420T3 (es) 2018-10-25
HUE049573T2 (hu) 2020-10-28
CA3077732A1 (en) 2012-03-22
CA3079450A1 (en) 2012-03-22
US20130296394A1 (en) 2013-11-07
AU2011301932C1 (en) 2016-09-01
PT2616068T (pt) 2016-09-13
AU2011301901B2 (en) 2016-02-11
IL225282A0 (en) 2013-06-27
MY168763A (en) 2018-12-04
US20140057958A1 (en) 2014-02-27
CN103200941A (zh) 2013-07-10
MY161607A (en) 2017-04-28
EP2616066A1 (en) 2013-07-24
US20160354346A1 (en) 2016-12-08
ZA201302193B (en) 2013-11-27
RU2013116403A (ru) 2014-10-27
CN105412092A (zh) 2016-03-23
TW201240662A (en) 2012-10-16
HUE039090T2 (hu) 2018-12-28
CY1121024T1 (el) 2019-12-11
TW201305117A (zh) 2013-02-01
DK3050564T3 (da) 2019-11-25
BR112013006320A2 (pt) 2016-06-21
EP3636263B1 (en) 2021-11-03
JP2013541527A (ja) 2013-11-14
CA3122745A1 (en) 2012-03-22
EP3050563B1 (en) 2018-05-09
US8653123B2 (en) 2014-02-18
KR102139905B1 (ko) 2020-07-31
CL2013000733A1 (es) 2013-08-23
EP2616068A1 (en) 2013-07-24
KR20200091507A (ko) 2020-07-30
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
ZA201302194B (en) 2013-11-27
MY173846A (en) 2020-02-24
SG188573A1 (en) 2013-04-30
WO2012037490A1 (en) 2012-03-22
EP3659600A1 (en) 2020-06-03
CY1122958T1 (el) 2021-10-29
EP3348264B1 (en) 2020-01-01
SG188571A1 (en) 2013-04-30
KR102354097B1 (ko) 2022-01-20
CY1122809T1 (el) 2021-05-05
EP2616069B1 (en) 2016-11-16
CA2812197A1 (en) 2012-03-22
ES2593612T3 (es) 2016-12-12
AR083018A1 (es) 2013-01-23
KR20200044147A (ko) 2020-04-28
PL3338777T3 (pl) 2020-07-13
WO2012037484A1 (en) 2012-03-22
HUE047476T2 (hu) 2020-04-28
BR112013006320B1 (pt) 2022-08-30
HK1257416A1 (en) 2019-10-18
IL225280A0 (en) 2013-06-27
RU2013116541A (ru) 2014-10-27
SG188572A1 (en) 2013-04-30
DK3338777T3 (da) 2020-04-20
MY191369A (en) 2022-06-20
US20120149746A1 (en) 2012-06-14
EP3698789A1 (en) 2020-08-26
DK3636263T3 (da) 2022-01-10
BR112013006355A2 (pt) 2016-06-28
US20120122945A1 (en) 2012-05-17
ES2904479T3 (es) 2022-04-05
PL3053576T3 (pl) 2018-11-30
JP6073229B2 (ja) 2017-02-01
US8492557B2 (en) 2013-07-23
DK3053576T3 (en) 2018-08-20
AU2011301932A1 (en) 2013-05-02
CA2812195A1 (en) 2012-03-22
CN103200941B (zh) 2015-12-16
HK1185539A1 (zh) 2014-02-21
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21

Similar Documents

Publication Publication Date Title
ES2613509T3 (es) Profármacos de ésteres de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol
AU2011301856B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
HK40028884B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40028884A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK1185540B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol